Efficacy of subcutaneous allergen immunotherapy in atopic dogs: A retrospective study of 664 cases.
Evelien E M FennisCatharina M M van DammeYvette M SchlotterJacqueline D SinkeMieke H G LeistraRichard T BartelsFemke BroerePublished in: Veterinary dermatology (2022)
In 59.9% of atopic dogs, subcutaneous ASIT can improve clinical signs by ≥50%. The beneficial effect of ASIT is higher if dogs are re-examined regularly and if systemic long-term corticosteroids are avoided, at least during the first 9 months of ASIT.
Keyphrases